SCHEMBL6095648

SCHEMBL6095648

FC(F)(F)CCOCc1ccccc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.50
CHRM3 P20309 1/20 0.42
TAAR1 Q96RJ0 3/20 0.39
ALDH1A1 P00352 2/20 0.38
PARP10 Q53GL7 1/20 0.37
AR P10275 1/20 0.36
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP12 P39900 1/20 0.35
FFAR1 O14842 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
PYCR1 P32322 1/20 0.34
MAPT P10636 2/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18171748 0.84 IDO1 (0.61) IDO1CHRM3TAAR1ALDH1A1PARP10
SCHEMBL10457912 0.81 IDO1 (0.53) IDO1CHRM3TAAR1ALDH1A1PARP10
SCHEMBL18171753 0.80 IDO1 (0.57) IDO1CHRM3TAAR1ALDH1A1PARP10
SCHEMBL18171754 0.80 IDO1 (0.57) IDO1CHRM3TAAR1ALDH1A1PARP10
SCHEMBL3865796 0.80 IDO1 (0.67) IDO1CHRM3TAAR1ALDH1A1PARP10
SCHEMBL15845948 0.79 IDO1 (0.55) IDO1CHRM3TAAR1ALDH1A1PARP10
SCHEMBL2400375 0.79 IDO1 (0.55) IDO1CHRM3TAAR1ALDH1A1PARP10
SCHEMBL7222677 0.77 IDO1 (0.53) IDO1CHRM3TAAR1ALDH1A1PARP10
SCHEMBL6097552 0.77 IDO1 (0.53) IDO1CHRM3TAAR1ALDH1A1PARP10
SCHEMBL15845873 0.76 TAAR1 (0.59) IDO1CHRM3TAAR1PYCR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US claimed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 EP claimed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US claimed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 WO claimed
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US disclosed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 EP disclosed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US disclosed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors IL1B, IL1A, TNF IDO1 323/4885CHRM3 4868/4885TAAR1 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.